Reprogenix

Founded in 2014 and based in Hangzhou, China, Reprogenix Bioscience Inc. , doing business as Reprogenix, specializes in the development of cell therapy solutions. The company has undergone strategic pivots to enhance its operational capabilities. In November 2025, Reprogenix raised CNY 500 million in series A funding from returning investors Lotus Lake Capital, Beijia Investment Management, with participation from China Reform Holdings, Fuzhe Capital, GAGE Capital, Orient Jiafu Asset Management, Sinowisdom, YuanBio Venture, Zhejiang Yuhang Industrial Transformation & Upgrading Investment, Yuansheng Venture Capital, along with other investors.

The company possesses an independently developed innovative technology platform for human pluripotent stem cells, including a stem cell line establishment platform, a stem cell directed differentiation platform, a gene editing platform, a molecular detection platform, a single-cell detection platform, and a sequencing data analysis platform. It has also independently developed products such as RGB5088 pancreatic islet cell injection. The company generates revenue by developing and providing stem cell regenerative medicine and other related products. The company will use the November 2025 funding to advance its core pipeline, develop an AI-based islet differentiation platform, improve its cell production system, and support international expansion.